Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter Thorén is active.

Publication


Featured researches published by Peter Thorén.


The EMBO Journal | 1998

Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1

Lilian Wikström; Catarina Johansson; Carmen Saltó; Carrolee Barlow; Angel Campos Barros; Frank Baas; Douglas Forrest; Peter Thorén; Björn Vennström

Thyroid hormone, acting through several nuclear hormone receptors, plays important roles in thermogenesis, lipogenesis and maturation of the neonatal brain. The receptor specificity for mediating these effects is largely unknown, and to determine this we developed mice lacking the thyroid hormone receptor TRα1. The mice have an average heart rate 20% lower than that of control animals, both under normal conditions and after thyroid hormone stimulation. Electrocardiograms show that the mice also have prolonged QRS‐ and QTend‐durations. The mice have a body temperature 0.5°C lower than normal and exhibit a mild hypothyroidism, whereas their overall behavior and reproduction are normal. The results identify specific and important roles for TRα1 in regulation of tightly controlled physiological functions, such as cardiac pacemaking, ventricular repolarisation and control of body temperature.


Nature Genetics | 1999

Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression

Jianming Wang; Hans Wilhelmsson; Caroline Graff; Hong Li; Anders Oldfors; Pierre Rustin; Jens C. Brüning; C R Kahn; David A. Clayton; Gregory S. Barsh; Peter Thorén; Nils-Göran Larsson

Mutations of mitochondrial DNA (mtDNA) cause several well-recognized human genetic syndromes with deficient oxidative phosphorylation and may also have a role in ageing and acquired diseases of old age. We report here that hallmarks of mtDNA mutation disorders can be reproduced in the mouse using a conditional mutation strategy to manipulate the expression of the gene encoding mitochondrial transcription factor A (Tfam, previously named mtTFA), which regulates transcription and replication of mtDNA (Refs 6,7). Using a loxP-flanked Tfam allele (TfamloxP; ref. 8) in combination with a cre-recombinase transgene under control of the muscle creatinine kinase promoter9,10, we have disrupted Tfam in heart and muscle. Mutant animals develop a mosaic cardiac-specific progressive respiratory chain deficiency, dilated cardiomyopathy, atrioventricular heart conduction blocks and die at 2-4 weeks of age. This animal model reproduces biochemical, morphological and physiological features of the dilated cardiomyopathy of Kearns-Sayre syndrome. Furthermore, our findings provide genetic evidence that the respiratory chain is critical for normal heart function.


Nature Medicine | 1999

Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor

Philippe Naveilhan; Hessameh Hassani; Josep M. Canals; A. Jonas Ekstrand; Åsa Larefalk; Vijay Chhajlani; Ernest Arenas; Karin Gedda; Lennart Svensson; Peter Thorén; Patrik Ernfors

Neuropeptide Y (NPY), a 36-amino-acid peptide widely expressed in the brain is involved in many physiological responses, including hypothalamic control of food intake and cardiovascular homeostasis. NPY mediates its effects through binding to the Y1, Y2 and Y5 G-protein-coupled receptors. Little is known of the role of the Y2 receptor in mediating the different NPY effects. We inactivated the Y2 receptor subtype in mice and found that these mice developed increased body weight, food intake and fat deposition. The null mutant mice showed an attenuated response to leptin administration but a normal response to NPY-induced food intake and intact regulation of re-feeding and body weight after starvation. An absence of the Y2 receptor subtype also affected the basal control of heart rate, but did not influence blood pressure. These findings indicate an inhibitory role for the Y2 receptor subtype in the central regulation of body weight and control of food intake.


Psychiatry Research-neuroimaging | 1981

Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls

Lars Oreland; Åsa Wiberg; Marie Åsberg; Lil Träskman; Lars Sjöstrand; Peter Thorén; Leif Bertilsson; Gunnel Tybring

Platelet monoamine oxidase (MAO) activity and cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5HIAA), homovanillic acid (HVA), and 4-hydroxy-3-methoxyphenylglycol (HMPG) were simultaneously measured in 20 currently depressed patients, 11 recovered depressed patients, 15 nondepressed suicide attempters, and 42 healthy control subjects. Both 5HIAA and HVA were positively and significantly correlated to platelet MAO activity in the healthy subjects, but not in any of the patient groups. Suicide attempters had significantly lower CSF 5HIAA than nonsuicidal patients.


Medicine and Science in Sports and Exercise | 1990

Endorphins and exercise: physiological mechanisms and clinical implications

Peter Thorén; John S. Floras; P. Hoffmann; Douglas R. Seals

In this paper we discuss recent experimental and clinical findings which lead us to propose that prolonged rhythmic exercise can activate central opioid systems by triggering increased discharge from mechanosensitive afferent nerve fibers (Group III or A-delta) arising from contracting skeletal muscle. We review evidence that supports the concept that many of the cardiovascular, analgesic, and behavioral effects of exercise are mediated by this mechanism and that the same or similar mechanisms are responsible for the central and peripheral effects of acupuncture. Based on this hypothesis, and supporting evidence from human and animal studies, we suggest a mechanism and a potential therapeutic role for exercise in the treatment of selected patients with disorders as diverse as hypertension, addiction, depression, and anorexia nervosa.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2006

Expression of Neutrophil Gelatinase–Associated Lipocalin in Atherosclerosis and Myocardial Infarction

Anne-Louise Hemdahl; Anders Gabrielsen; Chaoyong Zhu; Per Eriksson; Ulf Hedin; Jens Kastrup; Peter Thorén; Göran K. Hansson

Objective—Neutrophil gelatinase-associated lipocalin (NGAL) modulates the activity of matrix metalloproteinase (MMP) 9, an important mediator of vascular remodeling and plaque instability in atherosclerosis. This study aimed to analyze the expression of NGAL in atherosclerotic plaques and myocardial infarction (MI). Methods and Results—Atherosclerotic apolipoprotein E (apoE)−/− × low-density lipoprotein receptor (LDLR)−/− and C57BL/6J control mice were exposed to brief hypoxic stress (10 minutes of 10% oxygen). Expression of the mouse NGAL homolog (24p3) and MMP-9 was analyzed 48 hours later by quantitative RT-PCR, immunohistochemistry, and zymography. Hypoxic stress increased NGAL/24p3 mRNA in the cardiac vasculature. NGAL/24p3 was also increased in atherosclerotic plaques of apolipoprotein E−/− × LDLR−/− mice compared with C57BL/6J mice. Mice developing MI exhibited the highest plaque mRNA expression of NGAL/24p3 and MMP-9. Zymography revealed strong proteolytic activity in areas rich in 24p3 and MMP-9 protein. Immunohistochemistry performed on human carotid endarterectomy specimens and control tissue from the internal mammary artery showed colocalization of MMP-9 and NGAL with macrophages in the atherosclerotic plaques. Conclusions—NGAL/24p3 is increased in atherosclerotic plaques and MI. Colocalization with MMP-9 in areas with high-proteolytic activity suggests a role for NGAL/24p3 in modulating the MMP-9-mediated remodeling of plaques and infarcted hearts.


Acta Psychiatrica Scandinavica | 1984

CSF monoamine metabolites in melancholia

Marie Åsberg; Leif Bertilsson; Björn Mårtensson; G. P. Scalia-Tomba; Peter Thorén; L. Träskman‐Bendz

ABSTRACT– The neurotransmitter metabolites 5‐hydroxyindoleacetic acid (5‐HIAA), homovanillic acid (HVA) and 4‐hydroxy‐3‐methoxy‐phenyl glycol (HMPG) in cerebrospinal fluid (CSF) were measured by mass fragmentography in 83 patients with melancholia (diagnosed by the Newcastle Inventory and the Research Diagnostic Criteria), and 66 healthy volunteer controls. After adjustment by analysis of covariance for differences between the subject groups in body height, age and sex distribution, significantly (P < 0.001) lower concentrations of 5‐HIAA and HVA were found in the melancholia patients than in the controls. HMPG did not differ between the groups. The differences could not be accounted for by differences in timing or examination techniques, and not by previously administered drugs (all patients were drug‐free at the examination, but a minority had taken small amounts of psychotropic drugs prior to the wash‐out period). The differences persisted after excluding the suicidal patients. There were no clear‐cut differences between unipolar and bipolar patients. It is suggested that the reduced concentrations of 5‐HIAA and HVA in the melancholic patients may be due to altered serotonin and/or dopamine functions in the central nervous system, which may be connected with an increased vulnerability to certain types of affective illness.


Nature | 2001

Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor

Philippe Naveilhan; Hessameh Hassani; Guilherme Lucas; Karin Hygge Blakeman; Jing-Xia Hao; Xiao-Jun Xu; Zsuzsanna Wiesenfeld-Hallin; Peter Thorén; Patrik Ernfors

Neuropeptide Y (NPY) is believed to exert antinociceptive actions by inhibiting the release of substance P and other ‘pain neurotransmitters’ in the spinal cord dorsal horn. However, the physiological significance and potential therapeutic value of NPY remain obscure. It is also unclear which receptor subtype(s) are involved. To identify a possible physiological role for the NPY Y1 receptor in pain transmission, we generated NPY Y1 receptor null mutant (Y1-/-) mice by homologous recombination techniques. Here we show that Y1-/- mice develop hyperalgesia to acute thermal, cutaneous and visceral chemical pain, and exhibit mechanical hypersensitivity. Neuropathic pain is increased, and the mice show a complete absence of the pharmacological analgesic effects of NPY. In the periphery, Y1 receptor activation is sufficient and required for substance P release and the subsequent development of neurogenic inflammation and plasma leakage. We conclude that the Y1 receptor is required for central physiological and pharmacological NPY-induced analgesia and that its activation is both sufficient and required for the release of substance P and initiation of neurogenic inflammation.


Circulation | 2001

Vascular Endothelial Growth Factor-B–Deficient Mice Display an Atrial Conduction Defect

Karin Aase; Gabriel von Euler; Xuri Li; Annica Ponten; Peter Thorén; Renhai Cao; Yihai Cao; Birgitta Olofsson; Samuel Gebre-Medhin; Milos Pekny; Kari Alitalo; Christer Betsholtz; Ulf J. Eriksson

Background—Vascular endothelial growth factors (VEGFs) and their receptors are essential regulators of vasculogenesis and angiogenesis in both embryos and adults. One of the factors with a still unknown physiological function is VEGF-B, which is expressed in many tissues, including the heart. Methods and Results—Mice carrying a targeted deletion in the VEGF-B gene were developed. In VEGF-B−/− animals, no gross abnormalities were observed in organs that normally show high expression of VEGF-B, such as the heart, muscle, and kidney. Analysis of heart function by ECG showed that adult VEGF-B−/− mice have an atrial conduction abnormality characterized by a prolonged PQ interval. VEGF- or basic fibroblast growth factor–induced corneal angiogenesis was similar in normal and VEGF-B−/− mice. Conclusions—VEGF-B seems to be required for normal heart function in adult animals but is not required for proper development of the cardiovascular system either during development or for angiogenesis in adults.


The EMBO Journal | 2002

Retardation of post-natal development caused by a negatively acting thyroid hormone receptor α1

Alexander Tinnikov; Kristina Nordström; Peter Thorén; Jenny M. Kindblom; Stephen Malin; Björn Rozell; Maria Adams; Odelia Rajanayagam; Sven Pettersson; Claes Ohlsson; Krishna Chatterjee; Björn Vennström

Most patients with the syndrome resistance to thyroid hormone (RTH) express a mutant thyroid hormone receptor β (TRβ) with transdominant negative transcriptional effects. Since no patient with a mutant TRα has been identified, we introduced a point mutation into the mouse thyroid hormone receptor (TRα1) locus originally found in the TRβ gene, that reduces ligand binding 10‐fold. Heterozygous 2‐ to 3‐week‐ old mice exhibit a severe retardation of post‐natal development and growth, but only a minor reduction in serum thyroxine levels. Homozygous mice died before 3 weeks of age. Adult heterozygotes overcome most of these defects except for cardiac function abnormalities, suggesting that other factors compensate for the receptor defect. However, the additional deletion of the TRβ gene in this mouse strain caused a 10‐fold increase in serum thyroxine, restored hormonal regulation of target genes for TRs, and rescued the growth retardation. The data demonstrate a novel array of effects mediated by a dominant negative TRα1, and may provide important clues for identification of a potentially unrecognized human disorder and its treatment.

Collaboration


Dive into the Peter Thorén's collaboration.

Top Co-Authors

Avatar

P. Hoffmann

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Weiguo Zhang

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge